Anti-Ischaemic Efficacy and Tolerability of Trimetazidine in Elderly Patients with Angina Pectoris

Objective: Conventional anti-anginal agents may be associated with significant adverse effects in the elderly, often a direct consequence of their haemodynamic action. Trimetazidine is a metabolic agent, which acts at the myocardial mitochondrial level to exert an anti-ischaemic effect in the absence of significant haemodynamic changes. It may therefore be a particularly useful drug in the elderly. The aim of this open, multicentre study was to assess the anti-ischaemic efficacy and tolerability of trimetazidine when added to existing anti-anginal therapy in elderly patients with angina pectoris.